PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Drug: TAK-676; Drug: Carboplatin; Drug: 5-FU; Drug: Paclitaxel; Combination Product: TAK-676 + Carboplatin; Combination Product: Carboplatin + Paclitaxel; Combination Product: Carboplatin + 5-FU; Combination Product: TAK-676 + Carboplatin + 5-FU; Combination Product: TAK-676 + Carboplatin + Paclitaxel Sponsors: Presage Biosciences; Takeda Completed

https://clinicaltrials.gov/study/NCT06062602

Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials